OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
Е. Л. Насонов, Eugen Feist
Rheumatology Science and Practice (2022) Vol. 60, Iss. 5, pp. 505-518
Open Access | Times Cited: 12
Е. Л. Насонов, Eugen Feist
Rheumatology Science and Practice (2022) Vol. 60, Iss. 5, pp. 505-518
Open Access | Times Cited: 12
Showing 12 citing articles:
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
Е. Л. Насонов, А. М. Сатыбалдыев, Э. Н. Оттева, et al.
Rheumatology Science and Practice (2024) Vol. 62, Iss. 4, pp. 348-364
Open Access | Times Cited: 1
Е. Л. Насонов, А. М. Сатыбалдыев, Э. Н. Оттева, et al.
Rheumatology Science and Practice (2024) Vol. 62, Iss. 4, pp. 348-364
Open Access | Times Cited: 1
Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
А. А. Баранов, I. B. Vinogradova, О. Н. Аношенкова, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 3, pp. 307-319
Open Access | Times Cited: 3
А. А. Баранов, I. B. Vinogradova, О. Н. Аношенкова, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 3, pp. 307-319
Open Access | Times Cited: 3
Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
A. A. Akimova, N. E. Banshchikova, А. Э. Сизиков, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 1, pp. 25-33
Open Access | Times Cited: 2
A. A. Akimova, N. E. Banshchikova, А. Э. Сизиков, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 1, pp. 25-33
Open Access | Times Cited: 2
Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy
N. A. Lapkina, А. А. Баранов, N. Yu. Levshin, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 4, pp. 475-484
Open Access | Times Cited: 2
N. A. Lapkina, А. А. Баранов, N. Yu. Levshin, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 4, pp. 475-484
Open Access | Times Cited: 2
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic
A. A. Akimova, N. E. Banshchikova, A E Sizikov, et al.
Doklady Biochemistry and Biophysics (2024) Vol. 518, Iss. 1, pp. 291-299
Closed Access
A. A. Akimova, N. E. Banshchikova, A E Sizikov, et al.
Doklady Biochemistry and Biophysics (2024) Vol. 518, Iss. 1, pp. 291-299
Closed Access
Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors
А. А. Баранов, N. A. Lapkina, E. A. Leontyeva, et al.
Medical alphabet (2024) Vol. 1, Iss. 10, pp. 31-36
Closed Access
А. А. Баранов, N. A. Lapkina, E. A. Leontyeva, et al.
Medical alphabet (2024) Vol. 1, Iss. 10, pp. 31-36
Closed Access
Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
P. А. Shesternya, А. А. Баранов, I. B. Vinogradova, et al.
Modern Rheumatology Journal (2024) Vol. 18, Iss. 5, pp. 54-64
Open Access
P. А. Shesternya, А. А. Баранов, I. B. Vinogradova, et al.
Modern Rheumatology Journal (2024) Vol. 18, Iss. 5, pp. 54-64
Open Access
Development and validation of a high-performance liquid chromatography with tandem mass spectrometry method for quantification of tofacitinib in human plasma
Е. S. Vetrova, P. K. Karnakova, N. S. Bagaevа, et al.
Drug development & registration (2024)
Open Access
Е. S. Vetrova, P. K. Karnakova, N. S. Bagaevа, et al.
Drug development & registration (2024)
Open Access
Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study
А. Е. Каратеев, Е. Yu. Polishchuk, Е. С. Филатова, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 10
Open Access
А. Е. Каратеев, Е. Yu. Polishchuk, Е. С. Филатова, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 10
Open Access
Treatment of rheumatic diseases. Different nosologies, common problems
Yu. A. Olyunin
Modern Rheumatology Journal (2023) Vol. 17, Iss. 2, pp. 86-92
Open Access
Yu. A. Olyunin
Modern Rheumatology Journal (2023) Vol. 17, Iss. 2, pp. 86-92
Open Access
Experience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes
N. A. Lapkina, А. А. Баранов, N. E. Abaytova, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 5, pp. 554-561
Open Access
N. A. Lapkina, А. А. Баранов, N. E. Abaytova, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 5, pp. 554-561
Open Access
Blockade of the interleukin-6 signaling pathway in rheumatoid arthritis: Effects on obesity, adipocytokines and glucose metabolism
L. V. Kondratyeva, Yu. N. Gorbunova, Т. В. Попкова, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 6, pp. 658-666
Open Access
L. V. Kondratyeva, Yu. N. Gorbunova, Т. В. Попкова, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 6, pp. 658-666
Open Access
